| Datum |
Källa |
Rubrik |
Typ |
Alternativ |
| 2024-06-14 |
Biosergen |
Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-06-12 |
Biosergen |
Biosergen AB: Biosergen to welcome two new board members based on election at the Annual General Meeting |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-06-11 |
Carlsquare |
Carlsquare: Final permission received, BSG005 to reach patients |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-06-11 |
Biosergen |
Biosergen AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-06-11 |
Biosergen |
Biosergen AB: BioStock: Biosergen på väg mot första patientstudien med svampdödande behandling |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-06-11 |
Biosergen |
Biosergen AB: BioStock: Biosergen towards first-in-patient trial with antifungal therapy |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-05-31 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for first quarter 2024 |
Rapporter |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-05-17 |
Biosergen |
Notice of annual general meeting in Biosergen AB |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-05-14 |
Biosergen |
Biosergen AB: BioStock: Biosergens vd "det är ett globalt hälsohot som kräver handling" |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-05-14 |
Biosergen |
Biosergen AB: BioStock: Biosergen's CEO - "this is a global health threat and it needs attention" |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-05-10 |
Biosergen |
Biosergen AB: Biosergen publishes 2023 annual report |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-04-16 |
Biosergen |
Biosergen AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-04-09 |
Biosergen |
Biosergen AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-26 |
Biosergen |
Biosergen AB: Biosergen announces the outcome in the rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-18 |
Biosergen |
Biosergen AB: BioStock Investor Pitch: Biosergen |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-18 |
Biosergen |
Biosergen AB: BioStock Investor Pitch: Biosergen |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-15 |
Biosergen |
Biosergen AB: Members of the board of directors and management subscribe in ongoing rights issue |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-13 |
Carlsquare |
Carlsquare: Research update Biosergen: Rights issue to fund crucial step for lead project |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-12 |
Biosergen |
Biosergen AB: BioStock: Emission ska ta Biosergen till första effektdata i människa |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-12 |
Biosergen |
Biosergen AB: BioStock: Rights issue to give Biosergen first in-human efficacy data |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-08 |
Biosergen |
Biosergen AB: BioStock: Biosergen angriper osynliga hotet från svampinfektioner |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-08 |
Biosergen |
Biosergen AB: BioStock: Biosergen attacks invisible threat of fungal infections |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-07 |
Carlsquare |
Carlsquare: Carlsquare Equity Research interview with Biosergen |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-07 |
Biosergen |
Biosergen AB: Biosergens vd till BioStock: "Positiva data ger oss starkt erbjudande" |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-07 |
Biosergen |
Biosergen AB: Biosergen CEO to BioStock: "Positive data give us a strong value proposition" |
Pressreleaser |
Visa
Stäng
|
|
|
| 2024-03-05 |
Biosergen |
Biosergen AB: Biosergen publishes prospectus due to rights issue of units |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-03-01 |
Biosergen |
Bulletin from the extraordinary general meeting in Biosergen AB (publ) |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-02-29 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-02-12 |
Biosergen |
Biosergen AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-02-02 |
Carlsquare |
Carlsquare: Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-01-30 |
Biosergen |
Notice of Extraordinary general meeting in Biosergen AB |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-01-30 |
Biosergen |
Biosergen AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-01-16 |
Carlsquare |
Carlsquare: Research Update Biosergen: Licensing deal with Alkem and CTA submission |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-01-12 |
Biosergen |
Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2024-01-12 |
Biosergen |
Biosergen AB: Biosergen - Indian collaboration gives boost - Mangold Insight Analys |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-12-12 |
Biosergen |
Biosergen AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-12-11 |
Carlsquare |
Carlsquare: Biosergen, Carlsquare Nordic life science investor day |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-11-30 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for third quarter 2023 |
Rapporter |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-11-30 |
Biosergen |
Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ) |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-10-23 |
Biosergen |
Biosergen AB: Abstract presented at the 11th Trends in Medical Mycology publicly available |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-09-25 |
Biosergen |
Biosergen AB: Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-28 |
Biosergen |
Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-22 |
Biosergen |
The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-16 |
Carlsquare |
Carlsquare: Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-16 |
Biosergen |
Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-14 |
Biosergen |
Biosergen AB: Biosergen publishes interim report for first quarter 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-11 |
Biosergen |
Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
| 2023-08-11 |
Biosergen |
Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule.
|
| 2023-08-07 |
Biosergen |
Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) |
Pressreleaser |
Ladda ner
|
Visa
Stäng
|
|
|
